Somewhat Positive Media Coverage Somewhat Unlikely to Affect Corcept Therapeutics (CORT) Stock Price

Headlines about Corcept Therapeutics (NASDAQ:CORT) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corcept Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.7576577119279 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s analysis:

Several brokerages recently issued reports on CORT. Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Piper Jaffray Companies set a $30.00 price target on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Finally, BidaskClub upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Corcept Therapeutics presently has an average rating of “Buy” and a consensus target price of $21.00.

Shares of Corcept Therapeutics (NASDAQ CORT) opened at $18.73 on Friday. The company has a market cap of $2,140.00, a price-to-earnings ratio of 64.59 and a beta of 1.89. Corcept Therapeutics has a 52-week low of $6.70 and a 52-week high of $20.77.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.02). The company had revenue of $42.70 million during the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The business’s revenue was up 96.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.02 earnings per share. equities analysts forecast that Corcept Therapeutics will post 0.47 EPS for the current year.

In other news, Director G Leonard Baker, Jr. sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $17.59, for a total value of $527,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $16.72, for a total transaction of $133,760.00. Following the completion of the sale, the insider now directly owns 8,000 shares of the company’s stock, valued at approximately $133,760. The disclosure for this sale can be found here. Insiders own 19.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Corcept Therapeutics (CORT) Stock Price” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3128008/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-corcept-therapeutics-cort-stock-price.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.